Kazuko Itoh
Overview
Explore the profile of Kazuko Itoh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Komatsu W, Itoh K, Akutsu S, Kishi H, Ohhira S
Biosci Biotechnol Biochem
. 2017 Aug;
81(10):1956-1966.
PMID: 28812425
Nasunin is a major anthocyanin in eggplant peel. The purpose of this study was to examine the anti-inflammatory effects of nasunin in lipopolysaccharide (LPS)-stimulated RAW264 macrophages and to identify the...
2.
Tanaka M, Miyamura S, Imafuku T, Tominaga Y, Maeda H, Anraku M, et al.
Biol Pharm Bull
. 2016 Jun;
39(6):1000-6.
PMID: 27251502
A ferric citrate formulation for treating hyperphosphatemia is a new therapeutic that not only suppresses the accumulation of phosphorus in patients with chronic kidney disease-mineral bone disorders (CKD-MBD), but also...
3.
Tanaka M, Komaba H, Itoh K, Matsushita K, Matshushita K, Hamada Y, et al.
NDT Plus
. 2015 May;
1(Suppl 3):iii59-iii62.
PMID: 25983976
Background. The newer parathyroid hormone (PTH) assay, whole-PTH, uses an antibody that binds the region harbouring the first amino acid, making it specific for the complete molecule, 1-84-PTH. Especially among...
4.
Tanaka M, Nakanishi S, Komaba H, Itoh K, Matsushita K, Fukagawa M
NDT Plus
. 2015 May;
1(Suppl 3):iii49-iii53.
PMID: 25983974
Purpose. Secondary hyperparathyroidism with nodular hyperplasia is resistant to medical therapies. Cinacalcet is an effective treatment for severe secondary hyperparathyroidism. This multicentre retrospective study was designed to determine the long-term...
5.
Itoh K, Izumi Y, Inoue T, Inoue H, Nakayama Y, Uematsu T, et al.
Biochem Biophys Res Commun
. 2014 Sep;
453(3):356-61.
PMID: 25265491
Sodium reabsorption via Na-K-2Cl cotransporter 2 (NKCC2) in the thick ascending limbs has a major role for medullary osmotic gradient and subsequent water reabsorption in the collecting ducts. We investigated...
6.
Tanaka M, Itoh K, Matsushita K, Matsushita K, Moriishi M, Kawanishi H, et al.
Ther Apher Dial
. 2011 May;
15 Suppl 1:62-6.
PMID: 21595855
In addition to renal osteodystrophy, postmenopausal women on hemodialysis are at high risk for osteoporosis. Recent studies reported the effects of raloxifene, a selective estrogen receptor modulator for osteoporosis, in...
7.
Tanaka M, Tokunaga K, Maruyama T, Otagiri M, Tominaga Y, Itoh K, et al.
Ther Apher Dial
. 2011 May;
15 Suppl 1:38-41.
PMID: 21595851
Parathyroidectomy for hyperparathyroidism has been associated with a survival benefit, but the mechanisms remain unclear. We are reporting on an 88-year-old female patient who had high serum calcium and intact...
8.
Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, et al.
Ther Apher Dial
. 2011 Mar;
15(2):161-8.
PMID: 21426509
Treatment with a vitamin D receptor activator (VDRA) has survival benefits probably related to its effects beyond the traditional role in mineral metabolism. We hypothesized that VDRA reduces oxidative stress...
9.
Zecca M, Sessa S, Lin Z, Suzuki T, Sasaki T, Itoh K, et al.
Med Image Comput Comput Assist Interv
. 2010 Apr;
12(Pt 1):443-50.
PMID: 20426018
In recent years there has been an ever increasing amount of research and development of technologies and methodologies aimed at improving the safety of advanced surgery. In this context, several...
10.
Itoh K, Tanaka M, Hashiguchi J, Funakoshi S, Nakano H, Kubo H, et al.
Ther Apher Dial
. 2008 Apr;
12(2):126-32.
PMID: 18387160
Since hyperphosphatemia in hemodialysis patients can cause secondary hyperparathyroidism and promotes vascular calcification, serum phosphate (Pi) levels must be controlled by phosphate binders. Although sevelamer and colestimide are known as...